DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases.
DermBiont has raised $35.2M in total funding. The most recent round was Series B. The last funding was announced in October 2023.
DermBiont's investors include Civilization Ventures, Viking Global Investors, Valia Ventures, Joyance Partners, Toba Capital.
DermBiont is headquartered in Boston, United States.
DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases.
DermBiont is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"DermBiont — Funding & Investors." VCBacked, October 19, 2023, https://www.vcbacked.co/company/dermbiont. Accessed August 1, 2026.
VCBacked. (2023). DermBiont — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/dermbiont
{{cite web |title=DermBiont — Funding & Investors |url=https://www.vcbacked.co/company/dermbiont |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated